Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: tom jones who wrote (1358)	12/4/1997 3:34:00 PM
From: james	Read Replies (1) \| Respond to of 4676

tom, <<There was to be news about Isis 2302 phase II trials in 1997 but there doesn't seem to be any coming>>. Any info about 2302 in psoriasis? Should not take more than a year (if it is topical), the longer the worse. For RA, a bit longer. No need of buyout. Just one of these will put isip on the map. Trick (1) I-CAM is a reasonable, but not clearcut target. (2) is the pharm good enough to get enough 2301 on site? The later is my main concern. MZ could give us a better answer on this. I would just say my prayer. regards

To: tom jones who wrote (1358)	12/4/1997 3:36:00 PM
From: Joe Wesley	Read Replies (1) \| Respond to of 4676

Tom: The Isis research reports I have seen to date are not much help. Although anything can happen in a P3 trial, data Isis has released from open label trials of 2922 looks very good. The gild drug for CMVr is terrible (now causes uveitis)and it was approved. 2302 is a complicated story and I can only guess at the whole story however to fill some time here are my guesses: 1) 2302 Crohn's: Looks good high level of remissions key feature (PATIENTS CAN BE WEANED FROM STEROIDS). 2) 2302 Kidney transplant: University of Texas is very upbeat (presenting on it at Florence world wide conference Feb. 98). Trial is progressing slow because FDA is watching every patient in this trial. 3) 2302 Ulcerative Colitis: My guess is drug will be as good as Crohn's however this is a problem trial because a)FDA will not allow patients who are bleeding in the trial (most patients are bleeding) b) surgery is considered a cure (not in Crohn's) developing proper protocol is a big problem. IMO Isis is moving ahead here. 4) 2302 Psoriasis: From Inex article I have doubts here. 5) 2302 RA: This is the big one and I don't have any idea what is going on here other than first 20 patients didn't look as good as Crohn's patients. To understand what is going on you must separate to some extent 2302 from modulation of ICAM-1 by antisense in general. Isis is making much progress in delivery (Greg Hardee and others) and advanced generation compounds (medicinal chemistry) this all plays a part in whats going on. Dr. Crooke has the experience to get the job done let's pray things work out for him and us. Amateur